A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET)

NCT05214339 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma by BCLC Stage

Interventions

DRUG: Hepatic Arterial Infusion(mFOLFOX7) combined with Bevacizumab and Sintilimab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]
[object Object]
[object Object]